There are 3161 resources available
Uveal melanoma
Presenter: Josep Maria Piulats Rodriguez
Session: Non-cutaneous melanoma and non-melanoma skin cancers: There is much more we can do
Resources:
Slides
Webcast
Introduction and scientific background
Presenter: Fernanda Herrera
Session: Next generation of combinations in early clinical trials
Resources:
Webcast
Complexity of perioperative decisions in the era of novel therapies
Presenter: Alice Indini
Session: POWG 2: Optimal perioperative systemic treatment in different tumours
Resources:
Slides
Webcast
Difference between patient-centred and person-centred care: Patient advocate perspective
Presenter: Rachel Giles
Session: Cancer patients and advocacy
Resources:
Slides
Webcast
809MO - Efficacy and safety results from the phase II study of Timdarpacept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphoma
Presenter: Yuqin Song
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
Slides
Webcast
710MO - Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial
Presenter: Gemma Eminowicz
Session: Mini oral session 1: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
445MO - Dual inhibition of post-radiogenic angio-vasculogenesis in glioblastoma: Results of the phase I/II GLORIA trial
Presenter: Frank Giordano
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
507O - Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer: Final results of the phase II randomized multicenter LEANOX trial
Presenter: Eric Assenat
Session: Proffered paper session 1: GI tumours, lower
Resources:
Abstract
Slides
Webcast
341MO - Impact of aging on the genetic and transcriptional landscape of advanced breast cancer: an AURORA program (BIG 14-01) subanalysis
Presenter: Gabriele Zoppoli
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA85 - TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)
Presenter: Michiel van der Heijden
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast